Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Aspisol** is a Bayer brand of **lysine acetylsalicylate**, specifically DL-lysine monoacetylsalicylate, a water-soluble lysine salt of acetylsalicylic acid. It is an injectable salicylate nonsteroidal anti-inflammatory drug with analgesic, antipyretic, anti-inflammatory, and antiplatelet activity. The acetylsalicylate moiety irreversibly inhibits cyclooxygenase enzymes, reducing prostaglandin synthesis and platelet thromboxane A2 generation. Historical product information describes Aspisol as powder with solvent for preparation of an injection or infusion solution, used for acute pain, fever requiring rapid reduction, rheumatic disorders, superficial thrombophlebitis, and postoperative thrombosis and embolism prophylaxis. ([klinikum.uni-heidelberg.de](https://www.klinikum.uni-heidelberg.de/fileadmin/medizinische_klinik/Abteilung_3/pdf/ivandic/FI_aspisol.pdf))
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on lysine acetylsalicylate.